Scinus Group Secures €3 Million in Strategic Funding
Scinus Group, a company based in Utrecht, Netherlands, has announced the closure of a €3 million strategic funding round. This investment aims to enhance the global deployment of their Osilaris™ cell expansion platform. The platform is designed for automated and scalable cell culture, crucial for advanced cell therapy manufacturing.
Investment Details
The funding round was led by Myosotis Investments, with participation from Demcon Innovation Fund. This strategic investment is expected to accelerate the company's efforts in making cell therapies more accessible to patients worldwide.
Leadership Insights
Erik Vossenaar, who serves as the CEO and Executive Director of Scinus Group, expressed optimism about the funding, stating that it will significantly contribute to the company's mission of advancing cell therapy manufacturing. The company, founded in 2016, has been working on developing scalable solutions for stem cell cultivation, particularly focusing on point-of-care manufacturing of autologous, clinical-grade cell therapies.
Strategic Use of Funds
The newly acquired funds are earmarked for accelerating the global rollout of Scinus Group's Osilaris™ platform. This platform is integral to the company's strategy to streamline the manufacturing process of cell therapies, ensuring they are both controlled and reproducible.
Board Developments
Following the funding round, there are notable changes in the company's leadership structure. Dr. Janeska de Jonge will join the Board as a Non-Executive Director, representing Myosotis Investments. The company also anticipates the appointment of a third board member in the near future.
Scinus Group's commitment to innovation in cell therapy manufacturing positions them as a key player in the biotechnology sector. With this latest funding, the company is set to make significant strides in its mission to bring advanced cell therapies to a broader patient population.